Rubius Therapeutics Stock Price, News & Analysis (NASDAQ:RUBY)

-0.10 (-0.97 %)
(As of 09/23/2019 12:07 PM ET)
Today's Range
Now: $10.22
50-Day Range
MA: $10.34
52-Week Range
Now: $10.22
Volume25,888 shs
Average Volume264,336 shs
Market Capitalization$814.02 million
P/E RatioN/A
Dividend YieldN/A
Rubius Therapeutics, Inc focuses on the development of red cell therapeutics (RCTs) for the treatment of patients with severe diseases. The company is developing various RCTs, such as RTX-134 for treatment of phenylketonuria; RTX-Uricase for treatment of chronic refractory gout; RTX-CBS for treatment of homocystinuria; and RTX-OxOx for the treatment of second-line hyperoxaluria. Read More…

Industry, Sector and Symbol

Industry Biological products, except diagnostic
Current SymbolNASDAQ:RUBY



Sales & Book Value

Annual SalesN/A
Book Value$4.97 per share


Net Income$-89,190,000.00


Market Cap$814.02 million
Next Earnings Date11/12/2019 (Estimated)
OptionableNot Optionable

Receive RUBY News and Ratings via Email

Sign-up to receive the latest news and ratings for RUBY and its competitors with MarketBeat's FREE daily newsletter.

Rubius Therapeutics (NASDAQ:RUBY) Frequently Asked Questions

What is Rubius Therapeutics' stock symbol?

Rubius Therapeutics trades on the NASDAQ under the ticker symbol "RUBY."

How were Rubius Therapeutics' earnings last quarter?

Rubius Therapeutics Inc (NASDAQ:RUBY) announced its quarterly earnings data on Tuesday, August, 13th. The company reported ($0.50) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of ($0.46) by $0.04. During the same quarter in the prior year, the firm earned ($3.33) EPS. View Rubius Therapeutics' Earnings History.

When is Rubius Therapeutics' next earnings date?

Rubius Therapeutics is scheduled to release their next quarterly earnings announcement on Tuesday, November 12th 2019. View Earnings Estimates for Rubius Therapeutics.

What price target have analysts set for RUBY?

5 brokers have issued 12-month price objectives for Rubius Therapeutics' shares. Their predictions range from $4.00 to $40.00. On average, they expect Rubius Therapeutics' stock price to reach $25.00 in the next twelve months. This suggests a possible upside of 142.2% from the stock's current price. View Analyst Price Targets for Rubius Therapeutics.

What is the consensus analysts' recommendation for Rubius Therapeutics?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Rubius Therapeutics in the last year. There are currently 1 sell rating and 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Rubius Therapeutics.

What are Wall Street analysts saying about Rubius Therapeutics stock?

Here are some recent quotes from research analysts about Rubius Therapeutics stock:
  • 1. According to Zacks Investment Research, "Rubius Therapeutics, Inc. is a bio-technology company. It develops cellular therapies for the treatment of auto-immune, metabolic and other diseases. Rubius Therapeutics, Inc. is based in Cambridge, United States. " (7/24/2019)
  • 2. HC Wainwright analysts commented, "We have currently only assigned value to RTX-134 in PKU and RTX-240 in NSCLC. Our price target of $40/share is based on an equally-weighted composite of: (a) $40.7/share, as a 30x multiple of taxed and diluted $21.95 discounted back to FY19 at 20% (in line with the expected P/E multiple and discount rate of an early development-stage biotechnology company); and (b) an NPV of $39.4/share (discounted cash flow analysis using a 20% discount rate and 2.0% growth rate, in line with the expected discount and growth parameters of an early development-stage biotechnology company)." (6/26/2019)

Has Rubius Therapeutics been receiving favorable news coverage?

News headlines about RUBY stock have been trending somewhat negative this week, according to InfoTrie Sentiment Analysis. The research firm identifies positive and negative press coverage by monitoring more than six thousand blog and news sources in real-time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Rubius Therapeutics earned a media sentiment score of -1.3 on InfoTrie's scale. They also assigned media coverage about the company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an impact on the company's share price in the next several days. View News Stories for Rubius Therapeutics.

Who are some of Rubius Therapeutics' key competitors?

What other stocks do shareholders of Rubius Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Rubius Therapeutics investors own include Sorrento Therapeutics (SRNE), Momo (MOMO), TENCENT HOLDING/ADR (TCEHY), Venus Metals (VMC), Anavex Life Sciences (AVXL), Axsome Therapeutics (AXSM), ChemoCentryx (CCXI), Crispr Therapeutics (CRSP), Dicerna Pharmaceuticals (DRNA) and Lumentum (LITE).

Who are Rubius Therapeutics' key executives?

Rubius Therapeutics' management team includes the folowing people:
  • Mr. David R. Epstein, Exec. Chairman (Age 57)
  • Dr. Christopher L. Carpenter M.D., Ph.D., Chief Medical Officer (Age 63)
  • Dr. Pablo J. Cagnoni, CEO, Pres & Director (Age 56)
  • Mr. Andrew M. Oh, Chief Financial Officer (Age 47)
  • Ms. Joanne M. Protano, Sr. VP of Fin. & Operations (Age 50)

When did Rubius Therapeutics IPO?

(RUBY) raised $200 million in an initial public offering on Wednesday, July 18th 2018. The company issued 9,500,000 shares at a price of $20.00-$22.00 per share. J.P. Morgan, Morgan Stanley, Jefferies and Leerink Partners served as the underwriters for the IPO.

Who are Rubius Therapeutics' major shareholders?

Rubius Therapeutics' stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include Baillie Gifford & Co. (5.29%), Artal Group S.A. (3.54%), BlackRock Inc. (3.51%), Vanguard Group Inc. (3.40%), Nikko Asset Management Americas Inc. (1.57%) and Sumitomo Mitsui Trust Holdings Inc. (1.55%). Company insiders that own Rubius Therapeutics stock include Christopher L Carpenter, Francis M Cuss, Robert Langer and Torben Straight Nissen. View Institutional Ownership Trends for Rubius Therapeutics.

Which major investors are selling Rubius Therapeutics stock?

RUBY stock was sold by a variety of institutional investors in the last quarter, including EcoR1 Capital LLC, Artal Group S.A., Cormorant Asset Management LP, Janus Henderson Group PLC, Janus Henderson Group PLC, Morgan Stanley, BNP Paribas Arbitrage SA and LPL Financial LLC. Company insiders that have sold Rubius Therapeutics company stock in the last year include Christopher L Carpenter, Robert Langer and Torben Straight Nissen. View Insider Buying and Selling for Rubius Therapeutics.

Which major investors are buying Rubius Therapeutics stock?

RUBY stock was bought by a variety of institutional investors in the last quarter, including Sumitomo Mitsui Trust Holdings Inc., Nikko Asset Management Americas Inc., Vanguard Group Inc., Citadel Advisors LLC, ARK Investment Management LLC, BlackRock Inc., Nuveen Asset Management LLC and Baillie Gifford & Co.. View Insider Buying and Selling for Rubius Therapeutics.

How do I buy shares of Rubius Therapeutics?

Shares of RUBY can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Rubius Therapeutics' stock price today?

One share of RUBY stock can currently be purchased for approximately $10.32.

How big of a company is Rubius Therapeutics?

Rubius Therapeutics has a market capitalization of $821.99 million. The company earns $-89,190,000.00 in net income (profit) each year or ($2.27) on an earnings per share basis. Rubius Therapeutics employs 142 workers across the globe.View Additional Information About Rubius Therapeutics.

What is Rubius Therapeutics' official website?

The official website for Rubius Therapeutics is

How can I contact Rubius Therapeutics?

Rubius Therapeutics' mailing address is 399 BINNEY STREET SUITE 300, CAMBRIDGE MA, 02139. The company can be reached via phone at 617-679-9600 or via email at [email protected]

MarketBeat Community Rating for Rubius Therapeutics (NASDAQ RUBY)

Community Ranking:  2.3 out of 5 (star star)
Outperform Votes:  133 (Vote Outperform)
Underperform Votes:  155 (Vote Underperform)
Total Votes:  288
MarketBeat's community ratings are surveys of what our community members think about Rubius Therapeutics and other stocks. Vote "Outperform" if you believe RUBY will outperform the S&P 500 over the long term. Vote "Underperform" if you believe RUBY will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 9/23/2019 by Staff

Featured Article: Stock Symbol

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.

Yahoo Gemini Pixel